STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines

International Journal of Cancer

Volumn 120, Issue 1, 2007, Pages 189-195

  Fryknäs, Mårten ^a   Dhar, Sumeer ^a   Öberg, Fredrik ^a   Rickardson, Linda ^a   Rydåker, Maria ^a   Göransson, Hanna ^a   Gustafsson, Mats ^a   Pettersson, Ulf ^a   Nygren, Peter ^a   Larsson, Rolf ^a   Isaksson, Anders ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Drug resistance; Microarray; Radiation resistance; STAT1

Indexed keywords

DOXORUBICIN; FLUDARABINE; MESSENGER RNA; STAT1 PROTEIN; TYROSINE; VALSPODAR;

ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL STRAIN; CONTROLLED STUDY; CROSS RESISTANCE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MULTIMODALITY CANCER THERAPY; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CROSS REACTIONS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, RADIATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GAMMA RAYS; GENE EXPRESSION PROFILING; HUMANS; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RADIATION TOLERANCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VIDARABINE;

EID: 33845384469     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22291     Document Type: Article

References (48)

1. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-92.
2. Marples B, Joiner MC. Modification of survival by DNA repair modifiers: a probable explanation for the phenomenon of increased radioresistance. Int J Radiat Biol 2000;76:305-12.
3. Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, Yan Y, Malapetsa A, Alaoui-Jamali MA, Duncan AM, Panasci L. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 2002;62:5457-62.
4. Frit P, Canitrot Y, Muller C, Foray N, Calsou P, Marangoni E, Bourhis J, Salles B. Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammine-platinum(II): role of Ku autoantigen. Mol Pharmacol 1999;56:141-6.
5. Boeckman HJ, Trego KS, Turchi JJ. Cisplatin sensitizes cancer cells to ionizine radiation via inhibition of nonhomologous end joining. Mol Cancer Res 2005;3:277-85.
6. Kita K, Sugaya S, Zhai L, Wu YP, Wano C, Chigira S, Nomura J, Takahashi S, Ichinose M, Suzuki N. Involvement of LEU13 in interferon-induced refractoriness of human RSa cells to cell killing by X rays. Radiat Res 2003;160:302-8.
7. Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum RR. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA 2004;101:1714-19.
8. Rickardson L, Fryknas M, Dhar S, Lovborg H, Gullbo J, Rydaker M, Nygren P, Gustafsson MG, Larsson R, Isaksson A. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer 2005;93:483-92.
9. Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O'Dwyer PJ, Johnson SW. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 2005;92:1149-58.
10. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 1996;46:5125-30.
11. Larsson R, Nygren P, Ekberg M, Slater L. Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. Leukemia 1990;4:567-71.
12. Liminga G, Nygren P, Larsson R. Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. Exp Cell Res 1994;212:291-6.
13. Freshney I. Culture of animal cells: a manual of basic technique. 3rd edn. New York: Wiley-Liss, 1994.
14. Kaltenbach J, Kaltenbach M, Lyons W. Nigrosin as a dye for differentiating live and dead ascites cells. Exp Cell Res 1958;15:112-17.
15. Dimberg A, Nilsson K, Oberg F. Phosphorylation-deficient Stat1 inhibits retinoic acid-induced differentiation and cell cycle arrest in U-937 monoblasts. Blood 2000;96:2870-8.
16. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991;19:2499.
17. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol 2002;3:SOFTWARE0003.
18. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
19. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21.
20. Futscher BW, Blake LL, Gerlach JH, Grogan TM, Dalton WS. Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem 1993;213:414-21.
21. Li Y, Srivastava KK, Platanias LC. Mechanisms of type I interferon signaling in normal and malignant cells. Arch Immunol Ther Exp (Warsz) 2004;52:156-63.
22. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 1999;5:444-7.
23. Martinez-Lostao L, Briones J, Forne I, Martinez-Gallo M, Ferrer B, Sierra J, Rodriguez-Sanchez JL, Juarez C. Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2005;46:435-42.
24. Terui K, Haga S, Enosawa S, Ohnuma N, Ozaki M. Hypoxia/re-oxygenation- induced, redox-dependent activation of STAT1 (signal transducer and activator of transcription 1) confers resistance to apoptotic cell death via hsp70 induction. Biochem J 2004;380:203-9.
25. Fagard R, Mouas H, Dusanter-Fourt I, Devillers C, Bissieres P, Martin A, Lenoir G, VanTan H, Feuillard J, Raphael M. Resistance to fludarabine-induced apoptosis in Epstein-Barr virus infected B cells. Oncogene 2002;21:4473-80.
26. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997;100:2430-6.
27. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE. cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther 2001;299:434-41.
28. Levy DE, Darnell JE, Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651-62.
29. Sirota NP, Bezlepkin VG, Kuznetsova EA, Lomayeva MG, Milonova IN, Ravin VK, Gaziev AI, Bradbury RJ. Modifying effect in vivo of interferon α on induction and repair of lesions of DNA of lymphoid cells of γ-irradiated mice. Radiat Res 1996;146:100-5.
30. Savoldi-Barbosa M, Sakamoto-Hojo ET. Influence of interferon-γ on radiation-induced apoptosis in normal and ataxia-telangiectasia fibroblast cell lines. Teratog Carcinog Mutagen 2001;21:417-29.
31. Wittig R, Nessling M, Will RD, Mollenhauer I, Salowsky R, Munstermann E, Schick M, Helmbach H, Gschwendt B, Korn B, Kioschis P, Lichter P, et al. Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res 2002;62:6698-705.
32. Becker M, Sommer A, Kratzschmar JR, Seidel H, Pohlenz HD, Fichtner I. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 2005;4:151-68.
33. Patterson SG, Wei S, Chen X, Sallman DA, Gilvary DL, Zhong B, Pow-Sang J, Yeatman T, Djeu JY. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006.
34. Tahara E, Jr, Tahara H, Kanno M, Naka K, Takeda Y, Matsuzaki T, Yamazaki R, Ishihara H, Yasui W, Barrett JC, Ide T, Tahara E. GIP3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol Immunother 2005;54:729-40.
35. Martensen PM, Justesen J. Small ISGs coming forward. J Interferon Cytokine Res 2004;24:1-19.
36. Li L, Keating MJ, Plunkett W, Yang LY. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol Pharmacol 1997;52:798-806.
37. Yang LY, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol 1995;47:1072-9.
38. Blagosklonny MV. Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 2004;23:2967-75.
39. Basha G, Landuyt W, Fowler J, Vordermark D, Haustermans K, Geboes K, Van den Bogaert W, Yap SH, Lambin P, Penninckx F. An experimental evaluation of three preoperative radiation regimens for resectable rectal cancer. Ann Surg Oncol 2002;9:292-7.
40. Banasiak D, Barnetson AR, Odell RA, Mameghan H, Russell PJ. Comparison between the clonogenic, MTT, and SRB assays for determining radiosensitivity in a panel of human bladder cancer cell lines and a ureteral cell line. Radiat Oncol Investig 1999;7:77-85.
41. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54.
42. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000;19:2496-504.
43. Huang E, Cheng SH, Dressman H, Piltman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M, Nevins JR et al. Gene expression predictors of breast cancer outcomes. Lancet 2003;361:1590-6.
44. Gregory SA, Vose J, Modiano M, Kraemer K, Rifkin R, Rubin A, Menduni T, Ghalie R. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen. Leuk Lymphoma 2001;40:315-24.
45. Gregoire V, Hunter N, Brock WA, Milas L, Plunkett W, Hittelman WN. Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation. Int J Radiat Oncol Biol Phys 1994;30:363-71.
46. Gregoire V, Hunter N, Milas L, Brock WA, Plunkett W, Hittelman WN. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Res 1994;54:468-74.
47. Gregoire V, Van NT, Stephens LC, Brock WA, Milas L, Plunkett W, Hittelman WN. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 1994;54:6201-9.
48. Gregoire V, Ang KK, Rosier JF, Beauduin M, Garden AS, Hamoir M, Hittelman WN, Humblet Y, Khuri FR, Milas L, Mitine C, Sealliet P. A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. Radiother Oncol 2002;63:187-93.